Lethality in an anti-angiogenic tumor gene therapy model upon constitutive but not inducible expression of the soluble vascular endothelial growth factor receptor 1

2008 ◽  
Vol 10 (10) ◽  
pp. 1083-1091 ◽  
Author(s):  
Vijayshankar Ganesh Sivanandam ◽  
Sam Laurel Stephen ◽  
Ruben Hernandez-Alcoceba ◽  
Pilar Alzuguren ◽  
Maider Zabala ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Growth Factor Receptor ◽  
Inducible Expression ◽  
Vascular Endothelial ◽  
Tumor Gene Therapy ◽  
Therapy Model ◽  
Endothelial Growth Factor ◽  
Tumor Gene

Vascular Endothelial Growth Factor Receptor Upregulation in Response to Cell-Based Angiogenic Gene Therapy

2005 ◽  
Vol 79 (6) ◽  
pp. 2056-2063 ◽  
Author(s):  
Terrence M. Yau ◽  
Guangming Li ◽  
Yaoguang Zhang ◽  
Richard D. Weisel ◽  
Donald A.G. Mickle ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Growth Factor Receptor ◽  
Vascular Endothelial ◽  
Receptor Upregulation ◽  
Angiogenic Gene ◽  
Endothelial Growth Factor

scholarly journals Gene Therapy of Prostate Cancer with the Soluble Vascular Endothelial Growth Factor Receptor Fk1

2002 ◽  
Vol 1 (5) ◽  
pp. 548-553 ◽  
Author(s):  
Christian M. Becker ◽  
Filip A. Franebo ◽  
Irina Iordanescu ◽  
Danielle J. Behonick ◽  
Mei-Chiung Shih ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Gene Therapy ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Growth Factor Receptor ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor

Fortgeschrittenes medulläres Schilddrüsenkarzinom: Vandetanib verbessert das progressionsfreie Überleben

2012 ◽  
Vol 03 (02) ◽  
pp. 93-92
Author(s):  
Alexander Kretzschmar
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Phase Iii ◽  
Vascular Endothelial ◽  
Medulläres Schilddrüsenkarzinom ◽  
Epidermal Growth ◽  
Endothelial Growth Factor

Vandetanib ist ein oraler Hemmer des RET-Kinase-, VEGF (Vascular Endothelial Growth Factor Receptor)- und EGFR (Epidermal Growth Factor Receptor)-Signalwegs. In einer zulassungsrelevanten, randomisierten, doppelblinden, placebokontrollierten Phase- III-Studie verlängerte der Tyrosinkinasehemmer das progressionsfreie Überleben (PFS) signifikant länger als Placebo.

Sign in / Sign up

Export Citation Format

Share Document